RayKnowChina Research Map
Shortlist

Tongji University

同济大学

ShanghaiUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.1%Leads under 1 in 100 of China's research papers on NPC New since 2021

Led 3 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.09%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025
ThemesImaging & AI

Hospitals counted here

  1. Shanghai Tenth People's Hospital Counted in the group total1
  2. Infant Hospital Counted in the group total1
  3. Shanghai East Hospital, Tongji University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.9%Leads under 1 in 100 of China's research papers on ESCC

Led 25 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
1
Research papers it led
25
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025
ThemesNeoadjuvant & combined treatmentRadiotherapyMolecular markers & genomics

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shanghai East Hospital, Tongji University13
  2. Shanghai Pulmonary Hospital5
  3. Tongji Hospital3
  4. Shanghai Tenth People's Hospital3
  5. Yangpu Hospital Counted in the group total1
  6. Infant Hospital Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study.2024Nature medicineRCT
  2. Chemoradiotherapy for T1bN0M0 Esophageal Squamous Cell Carcinoma: A Practical Dilemma Delimited by Invasion Depth.2022Gastroenterology
  3. Investigating the impact of the inflammatory immune microenvironment and steroids or COX-2 inhibitors usage on immunotherapy in advanced esophageal squamous cell carcinoma (ESCC): a propensity score matched analysis.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  4. Survival risk stratification based on prognosis nomogram to identify patients with esophageal squamous cell carcinoma who may benefit from postoperative adjuvant therapy.2024BMC cancerFree full text
  5. Intramedullary spinal cord metastasis from esophageal squamous cell carcinoma: case report and literature review.2023BMC neurologyFree full text
Trials on ClinicalTrials.gov5
  1. Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell CarcinomaRecruitingNCT06304350Lead sponsorPhase 2Start 2024-02
  2. A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Study sitePhase 1Start 2022-10
  3. A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Study sitePhase 1Start 2024-03
  4. A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Active, not recruitingNCT05094336Study sitePhase 1/Phase 2Start 2022-02
  5. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
0.7%Leads under 1 in 100 of China's research papers on HCC

Led 102 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
0
Research papers it led
102
Trials it led
2
Share of China's trials
0.1%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shanghai East Hospital, Tongji University36
  2. Shanghai Tenth People's Hospital27
  3. Tongji Hospital Counted in the group total12
  4. Shanghai Fourth People's Hospital Counted in the group total7
  5. Yangpu Hospital Counted in the group total5
  6. Putuo People's Hospital4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.2023Gastroenterology
  2. Two sides of NNMT in alcoholic and non-alcoholic fatty liver development.2021Journal of hepatology
  3. Advancing microvascular invasion diagnosis: a multi-center investigation of novel MRI-based models for precise detection and classification in early-stage small hepatocellular carcinoma (≤ 3 cm).2025Abdominal radiology (New York)
  4. Radiomics with Machine Learning Improves the Prediction of Microscopic Peritumoral Small Cancer Foci and Early Recurrence in Hepatocellular Carcinoma.2025Academic radiology
  5. A Novel Nomogram for Prediction of Survival in Patients with Small Isolated Hepatocellular Carcinoma: A Population-Based and Externally Validated Study.2025Journal of investigative surgery : the official journal of the Academy of Surgical Research
Trials on ClinicalTrials.gov6
  1. First in Human Study of SIM0610 in Solid TumorsRecruitingNCT07348211Study sitePhase 1Start 2026-01
  2. Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid TumorsNot yet recruitingNCT07558200Study sitePhase 1Start 2026-05
  3. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06954467Study sitePhase 2Start 2025-05
  4. A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsNot yet recruitingNCT06724263Study sitePhase 2Start 2024-12
  5. A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Study sitePhase 1Start 2022-10
  6. B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular CarcinomaStatus unknownNCT05070156Lead sponsorEarly phase 1Start 2021-10

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
0.9%Leads under 1 in 100 of China's research papers on Stomach cancer

Led 84 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
0
Research papers it led
84
Trials it led
3
Share of China's trials
0.2%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025
ThemesNutrition & recoverySurgeryPeritoneal spread & advanced disease

Hospitals counted here

  1. Shanghai East Hospital, Tongji University37
  2. Shanghai Tenth People's Hospital21
  3. Tongji Hospital17
  4. Shanghai Fourth People's Hospital Counted in the group total3
  5. Infant Hospital Counted in the group total2
  6. Yangpu Hospital, Tongji University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer.2024Med (New York, N.Y.)RCT
  2. Tranditional Roux-en-Y vs Uncut Roux-en-Y in Laparoscopic Distal Gastrectomy: a Randomized Controlled Study.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractRCTFree full text
  3. First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.2024Signal transduction and targeted therapyFree full text
  4. The Value of Primary Tumor Resection in Patients with Liver Metastases: A 10-Year Outcome.2025Annals of surgical oncologyFree full text
  5. Indolent T-cell lymphoma of the gastrointestinal tract coexisting with gastric signet-ring cell carcinoma: A case report and review of literature.2025World journal of gastroenterologyFree full text
Trials on ClinicalTrials.gov6
  1. A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)RecruitingNCT07221149Study sitePhase 2/Phase 3Start 2026-03
  2. Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric CancerRecruitingNCT07366528Study sitePhase 3Start 2025-12
  3. SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing RegimenRecruitingNCT06123494Study sitePhase 3Start 2024-01
  4. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy ProcedureRecruitingNCT06081647Study siteN/AStart 2023-12
  5. A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingNCT05934331Study sitePhase 2Start 2023-07
  6. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01

PubMed searchClinicalTrials.gov

Hepatoblastoma

肝母细胞瘤
2.6%Leads about 1 in 38 of China's research papers on Hepatoblastoma ▼ from 3.5%

Led 4 of 154 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.6%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Shanghai Tenth People's Hospital3
  2. Shanghai Fourth People's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
1.1%Leads about 1 in 87 of China's research papers on Osteosarcoma ▼ from 1.9%

Led 26 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
26
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shanghai Tenth People's Hospital20
  2. Shanghai East Hospital, Tongji University2
  3. Tongji Hospital2
  4. Shanghai Fourth People's Hospital1
  5. People's Hospital, Tongji University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.8%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour

Led 4 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 222025

Hospitals counted here

  1. Shanghai East Hospital, Tongji University2
  2. Shanghai Pulmonary Hospital1
  3. Tongji Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.6%Leads under 1 in 100 of China's research papers on Neuroblastoma ▼ from 1.6%

Led 7 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 4420232024: 1120242025: 002025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shanghai East Hospital, Tongji University2
  2. Shanghai Tenth People's Hospital2
  3. Tongji Hospital2
  4. Infant Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
1.4%Leads about 1 in 70 of China's research papers on Myeloma

Led 24 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
1
Research papers it led
24
Trials it led
3
Share of China's trials
0.6%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 1120242025: 112025
ThemesDrug combinationsDiagnosis, MRD & riskRelapse & resistance

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shanghai East Hospital, Tongji University13
  2. Shanghai Tenth People's Hospital5
  3. Shanghai Fourth People's Hospital3
  4. Tongji Hospital2
  5. Yangpu Hospital Counted in the group total2
  6. Fourth People's Hospital of Tongji University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study.2023Clinical lymphoma, myeloma & leukemiaRCT
  2. Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS.2023Clinical lymphoma, myeloma & leukemiaRCT
  3. Characteristics and Outcomes of Second Primary Multiple Myeloma in Adult Cancer Survivors: A Population-Based Cohort Study.2025Cancer medicineFree full text
  4. Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis.2024Hematology (Amsterdam, Netherlands)
  5. Differential Performances in Lesions and Radiotracer of 18F-FDG PET/CT between Multiple Myeloma and Unknown Osteolytic Metastasis.2023Current medical imaging
Trials on ClinicalTrials.gov6
  1. Universal CAR-T Cell Therapy for MMRecruitingNCT07248176Lead sponsorN/AStart 2025-04
  2. OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMMRecruitingNCT06182696Study sitePhase 1/Phase 2Start 2023-10
  3. Efficacy and Safety Evaluation of BCMA-UCARTSuspendedNCT03752541Lead sponsorN/AStart 2019-11
  4. Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MMStatus unknownNCT04500431Lead sponsorPhase 1Start 2018-07
  5. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  6. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
0.0%Leads none of China's research papers on B-ALL

Led 0 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
1
Research papers it led
0
Trials it led
1
Share of China's trials
0.4%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.2%Leads under 1 in 100 of China's research papers on Aplastic anaemia ▼ from 2.9%

Led 1 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025
ThemesStem cell transplant

Hospitals counted here

  1. Shanghai East Hospital, Tongji University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Diagnosis and Management of Fanconi Anemia.2025Journal of evidence-based medicine

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
0.7%Leads under 1 in 100 of China's research papers on Haemophilia A New since 2021

Led 2 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.07%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

Hospitals counted here

  1. Yangpu Hospital1
  2. First Rehabilitation Hospital, Tongji University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led2
  1. Activity and participation in haemophiliacs: Item response modelling based on international classification of functioning, disability and health.2023Haemophilia : the official journal of the World Federation of Hemophilia
  2. Diagnostic Value of the HEAD-US-C Scale for the Knees of Severe Hemophilia A Patients.2024Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
0.4%Leads under 1 in 100 of China's research papers on Myasthenia gravis

Led 2 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.09%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025
ThemesStandard immunotherapy

Hospitals counted here

  1. East Hospital Counted in the group total1
  2. Shanghai East Hospital, Tongji University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
1.1%Leads about 1 in 93 of China's research papers on Takayasu arteritis New since 2021

Led 2 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Shanghai Tenth People's Hospital2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.6%Leads about 1 in 62 of China's research papers on Idiopathic pulmonary fibrosis ▼ from 4.0%

Led 16 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
16
Trials it led
1
Share of China's trials
1.4%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Shanghai Pulmonary Hospital6
  2. Shanghai East Hospital, Tongji University4
  3. Shanghai Tenth People's Hospital2
  4. Tongji Hospital2
  5. Shanghai Pulmonary Hospital, Tongji University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.6%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis

Led 5 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
1
Research papers it led
5
Trials it led
1
Share of China's trials
1.8%
Share of the world's papers
0.08%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 222025

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
1.4%Leads about 1 in 71 of China's research papers on Duchenne muscular dystrophy New since 2021

Led 3 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Infant Hospital2
  2. Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital of Tongji University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
0.0%Leads none of China's research papers on Behçet disease

Led 0 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
0
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.3%Leads under 1 in 100 of China's research papers on IgA nephropathy

Led 2 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Shanghai Pulmonary Hospital1
  2. Shanghai East Hospital, Tongji University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov